Inhibiting inflammatory enzyme after heart attack does not reduce risk of subsequent event

In patients who experienced an acute coronary syndrome event -- such as heart attack or unstable angina -- use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 -- believed to play a role in the development of atherosclerosis -- did not reduce the risk of recurrent major coronary events, according to a study.